Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis

PHASE3CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Endogenous Anterior Uveitis
Interventions
DRUG

Difluprednate 0.05% ophthalmic emulsion

1 drop in study eye, 4 times a day, for 14 days, followed by a 14-day tapering period dependent on the Investigator's determination of adequate response to treatment

DRUG

Prednisolone acetate 1.0% ophthalmic suspension

1 drop in study eye, 8 times a day, for 14 days, followed by a 14-day tapering period dependent on the Investigator's determination of adequate response to treatment

Trial Locations (1)

76134

Contact Alcon Call Center, Fort Worth

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Alcon Research

INDUSTRY